EUVEIN 500 Film-coated tablet Ref.[50596] Active ingredients: Diosmin Hesperidin

Source: Health Sciences Authority (SG)  Revision Year: 2021  Publisher: Manufacturer: General Drugs House Co.,Ltd., 2-4 Lardprao Road Soi 82, Bangkok, Thailand 10310

5.1. Pharmacodynamic properties

Venotonic and vascular protector.

Pharmacology

It is active upon the return vascular system in the following way:

  • it reduces venous distensibility and stasis,
  • in the microcirculation, it normalises capillary permeability and increases capillary resistance.

Clinical Pharmacology

Double blind controlled studies using methods by which the effects of the product on venous haemodynamics could be demonstrated and quantified have confirmed the above pharmacological properties in man.

Clinical trials

Double-blind placebo-controlled trials have demonstrated the activity of the drug in phlebology, in the treatment of chronic venous sufficiency of the lower limbs (both functional and organic).

5.2. Pharmacokinetic properties

In man, following oral administration of the substance containing Euvein:

  • excretion is mainly faecal, a mean of 14% of the dose administered is excreted in the urine.
  • the elimination half-life is 11 hours.
  • the drug extensively metabolised as evidence by the presence of various phenol acids in the urine.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.